Article

RP functional outcomes vary by race

African-American men report better sexual function but less satisfaction than Caucasians

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Sandip Prasad, MD, on the approval of mitomycin intravesical solution for LG-IR-NMIBC
Sandip Prasad, MD, on the approval of mitomycin intravesical solution for LG-IR-NMIBC
Jennifer Robles, MD, discusses the growing interest in HoLEP
Jennifer Robles, MD, discusses the growing interest in HoLEP
Suzanne Merrill, MD, on the rationale for BCG plus PD-1/PD-L1 inhibitors in high-risk NMIBC
Suzanne Merrill, MD, on the rationale for BCG plus PD-1/PD-L1 inhibitors in high-risk NMIBC
Related Content
FDA grants priority review to gepotidacin for uncomplicated urogenital gonorrhea
August 13th 2025

FDA grants priority review to gepotidacin for uncomplicated urogenital gonorrhea

Hannah Clarke
Pearls & Perspectives: Bringing the Magic Back to Medicine, with David Canes, MD
August 13th 2025

Pearls & Perspectives: Bringing the Magic Back to Medicine, with David Canes, MD

Amy M. Pearlman, MD
Health Canada approves perioperative durvalumab plus chemo for MIBC
August 13th 2025

Health Canada approves perioperative durvalumab plus chemo for MIBC

Hannah Clarke
Pearls & Perspectives: Tailoring BPH Therapies to the Patient, with Utsav Bansal, MD
August 13th 2025

Pearls & Perspectives: Tailoring BPH Therapies to the Patient, with Utsav Bansal, MD

Amy M. Pearlman, MD
FDA accepts NDA for new formulation of piflufolastat F 18 in prostate cancer
August 13th 2025

FDA accepts NDA for new formulation of piflufolastat F 18 in prostate cancer

Hannah Clarke
Urinary bladder cancer with organs and tumors or cancerous cells 3D rendering illustration with male body. Image Credit: © Matthieu - stock.adobe.com
August 13th 2025

First-line disitamab vedotin plus toripalimab under review in China for la/mUC

Hannah Clarke
© 2025 MJH Life Sciences

All rights reserved.